ARA 290 is a derivative of erythropoietin (EPO).1 In vivo, ARA 290 (0.8 and 8 nmol/kg, i.p.) reduces plasma creatine, urea, and aspartate aminotransferase (AST) levels, markers of renal dysfunction, in a rodent model of renal ischemia-reperfusion injury. It decreases wound area in a rat model of punch biopsy-induced dermal injury and a rat model of decubitus ulcer.2 ARA 290 (30 µg/kg, i.p.) reduces the latency to find the platform in the Morris water maze in a rat model of cortical impact-induced traumatic brain injury (TBI).3 It also reduces tactile allodynia in a rat model of neuropathic pain induced by spinal nerve injury (SNI).4
1.Brines, M., Patel, N.S.A., Villa, P., et al.Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietinProc. Natl. Acad. Sci. USA105(31)10925-10930(2008) 2.Erbayraktar, Z., Erbayraktar, S., Yilmaz, O., et al.Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healingMol. Med.15(7-8)235-241(2009) 3.Robertson, C.S., Garcia, R., Gaddam, S.S.K., et al.Treatment of mild traumatic brain injury with an erythropoietin-mimetic peptideJ. Neurotrauma30(9)765-774(2013) 4.Swartjes, M., Niesters, M., and Dahan, A.Assessment of allodynia relief by tissue-protective molecules in a rat model of nerve injury-induced neuropathic painMethods Mol. Biol.982187-195(2013)